ANI Pharmaceuticals, Inc.
ANIP
$95.20
-$0.15-0.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 211.37M | 197.12M | 190.57M | 148.33M | 138.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 211.37M | 197.12M | 190.57M | 148.33M | 138.04M |
| Cost of Revenue | 74.62M | 73.04M | 80.28M | 63.08M | 57.70M |
| Gross Profit | 136.76M | 124.09M | 110.29M | 85.26M | 80.34M |
| SG&A Expenses | 81.77M | 75.63M | 69.52M | 70.28M | 49.32M |
| Depreciation & Amortization | 23.28M | 22.89M | 22.60M | 15.75M | 14.70M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 196.20M | 182.12M | 189.05M | 159.23M | 129.01M |
| Operating Income | 15.17M | 15.00M | 1.53M | -10.89M | 9.03M |
| Income Before Tax | 10.53M | 19.99M | -13.76M | -31.50M | -2.29M |
| Income Tax Expenses | 1.98M | 4.31M | -3.49M | -7.33M | -- |
| Earnings from Continuing Operations | 8.55M | 15.68M | -10.28M | -24.17M | -2.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.55M | 15.68M | -10.28M | -24.17M | -2.29M |
| EBIT | 15.17M | 15.00M | 1.53M | -10.89M | 9.03M |
| EBITDA | 38.45M | 37.89M | 24.13M | 4.85M | 23.73M |
| EPS Basic | 0.37 | 0.70 | -0.55 | -1.27 | -0.14 |
| Normalized Basic EPS | 0.36 | 0.31 | -0.19 | -0.51 | 0.14 |
| EPS Diluted | 0.36 | 0.69 | -0.55 | -1.27 | -0.14 |
| Normalized Diluted EPS | 0.35 | 0.30 | -0.19 | -0.51 | 0.14 |
| Average Basic Shares Outstanding | 19.83M | 19.61M | 19.45M | 19.40M | 19.32M |
| Average Diluted Shares Outstanding | 20.31M | 20.05M | 19.45M | 19.40M | 19.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 4.76% | 2.59% | -3.95% | -1.68% | -17.80% |